Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Reports Fourth Quarter 2023 Financial Results
Summary
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth quarter revenue was $10.89 billion, 5% lower than the same quarter in 2022, while GAAP diluted EPS increased by 5% to $4.20. For the full year, revenue declined 5% to $42.86 billion, and GAAP diluted EPS was $15.45. The company also announced its annual guidance for 2024 with revenue expected between $42.1 billion and $43.3 billion.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement